PHR Earnings

PHR reported its earnings on 2026-03-19, showcasing a revenue of against an estimate of 127.89M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.1 by 0%. The stock experienced a 0.76% price change on the earnings day and a -4.16% change over the next five days, reflecting market reactions to the results.

Following PHR's earnings announcement on 2026-03-19, the stock price moved by 0.76% on the day of the release. Over the subsequent five days, it saw a -4.16% change. Historically, PHR's stock price tends to shift by an average of 3.9% in the 10 days leading up to earnings and 4.28% in the 10 days following, providing insight into potential market.

For 2027/Q1, analysts estimate PHR's annual revenue to reach 135.49M, while the EPS is projected at 0.09. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PHR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PHR's stock price typically moves by 3.9% in the 10 days before its earnings and 4.28% in the 10 days after. For the upcoming 2027/Q1 earnings, analysts expect an EPS of 0.09 and revenue of 135.49M.

The earnings call presented a mixed but generally positive outlook. The company achieved positive GAAP net income for the first time, showing profitability. Despite revenue reductions, the confidence in maintaining EBITDA guidance and ongoing margin expansion is promising. The strategic focus on AI, integration of AccessOne, and growth in Network Solutions and organic payments are positive indicators. While there are concerns about client spending and GLP-1 drugs, the overall sentiment and strategic direction suggest a likely positive stock price movement, especially for a small-cap stock with a market cap of $1.2 billion.